Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit

Rhea-AI Summary

Lumos Pharma's President & Chief Scientific Officer, John McKew, will participate in the Oppenheimer 2023 Life Sciences Summit. The Summit will provide an opportunity for discussions with investors about the company's clinical programs and corporate strategy.

Positive

• Lumos Pharma's participation in the Oppenheimer Life Sciences Summit could attract investor interest and potentially lead to new funding opportunities.

Negative

• No negative takes identified.

AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company’s President & Chief Scientific Officer, John McKew, PhD, will participate in the Oppenheimer 2023 Life Sciences Summit to be held July 18^th – 20^th in Montauk, NY, during which discussions with investors will take place.

Please contact your Oppenheimer sales representative to attend the Montauk Life Sciences Summit or Lumos Pharma Investor Relations with questions about our clinical programs and corporate strategy.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD subjects otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What is the Oppenheimer 2023 Life Sciences Summit?

The Oppenheimer 2023 Life Sciences Summit is an event where companies in the life sciences sector can connect with investors and discuss their clinical programs and corporate strategy.

Who will be participating from Lumos Pharma?

Lumos Pharma's President & Chief Scientific Officer, John McKew, will be participating in the Oppenheimer 2023 Life Sciences Summit.

What are the potential benefits of participating in the Summit?

Participating in the Oppenheimer Life Sciences Summit could attract investor interest and potentially lead to new funding opportunities for Lumos Pharma.

How can I attend the Montauk Life Sciences Summit?

To attend the Montauk Life Sciences Summit, please contact your Oppenheimer sales representative.

Who should I contact for questions about Lumos Pharma's clinical programs and corporate strategy?

For questions about Lumos Pharma's clinical programs and corporate strategy, please contact Lumos Pharma Investor Relations.